Compare Garmin Ltd. (GRMN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs IDEXX Laboratories, Inc. — how do they compare? Garmin Ltd. trades at $311.14 (market cap $59.72B), while IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays a 1.36% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GRMN | IDXX | |
|---|---|---|
Market Cap | $59.72B | $46.22B |
Sector | Technology | Health |
52-Week High | $313.16 | $766.68 |
52-Week Low | $187.10 | $526.44 |
Enterprise Value | $57.23B | $47.12B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $310.22, down 0.94% on the day, yet maintains a bullish technical trend with strong moving averages and support near $308. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 estimate, driven by 11% revenue growth. Profitability remains high, with a net margin of 24.47% and ROE of 21.89%, though valuation multiples like P/E of 31.96 appear elevated. Recent news highlights surging fitness segment demand and a raised 2026 outlook.
Garmin's outlook is supported by consistent earnings outperformance and growth in wearable technology, but risks include rich valuations and potential sales deceleration. Analyst consensus is a $318.67 price target with a Hold-heavy rating, suggesting cautious optimism amid near-term strength. The stock's proximity to its 52-week high warrants monitoring for sustainability of momentum.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
